FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:1776-1777 December 11, 1997 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Abenhaim, L. PubMed Citation

To the Editor: A growing body of evidence implicates the anorectic drug fenfluramine and its d-isomer, dexfenfluramine, in the development of pulmonary hypertension and valvular heart disease.^1,2 Pulmonary hypertension is thought to occur because of the vasoconstrictive effects of serotonin,² which may also lead to cardiac valvular lesions that appear morphologically similar to those found in the carcinoid syndrome.^2,3 We report on a patient in whom ischemic necrosis of the fingers developed shortly after the start of therapy with dexfenfluramine.

A 44-year-old man with non-insulin-dependent diabetes mellitus presented with a four-week history of pain and discoloration of the left . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Michelakis, E. D., Weir, E. K., Nelson, D. P., Reeve, H. L., Tolarova, S., Archer, S. L. (1999). Dexfenfluramine Elevates Systemic Blood Pressure by Inhibiting Potassium Currents in Vascular Smooth Muscle Cells. J. Pharmacol. Exp. Ther. 291: 1143-1149 [Abstract] [Full Text]